What is the product?
Purified ibogaine hydrochloride and root-based preparations are not interchangeable descriptions of exposure.
Safety context / 01
Dosing Explained
Ibogaine dose is not a number to copy. In research and medically supervised settings, decisions are shaped by product identity, screening findings, medications, cardiac risk, monitoring, and uncertainty. This page explains the logic—not a protocol—and it does not support self-administration.
Educational context only.
Never self-administer.
Never self-administer.
What “dose” leaves out / 02
A dose describes a decision made inside a system.
In published work, a number usually sits beside eligibility criteria, product specifications, medical observation, adverse-event reporting, and rules for stopping or excluding participants. Removing the number from that system removes much of its meaning. The broader safety context across Bright Basin 46 starts with that distinction: a dose is not a standalone measure of suitability.
Ibogaine is metabolized to noribogaine, and the two compounds do not have identical pharmacology or timing. The ibogaine overview notes its active metabolite, while study authors examine exposure, response, and adverse effects within controlled conditions. That is one reason an amount taken at one point in time cannot summarize the whole physiological picture.
Safety concern is not abstract. The U.S. Food and Drug Administration has published a regulatory discussion of QT prolongation and proarrhythmia, terms relevant to why cardiac evaluation and ongoing observation are central to conversations about substances with potential rhythm effects. No online explanation can substitute for clinical assessment or emergency capability.
Decision inputs / 03
Why “weight-based” is only one input.
Some literature reports amounts in relation to body weight. That format can make a complex decision look formulaic, but it is a reporting convention—not evidence that body weight alone determines safety or suitability. In supervised contexts, risk-based decisions may also weigh cardiovascular findings, current medications, substance use, organ function, prior reactions, product testing, and the ability to monitor and respond.
A compound’s metabolic pathway adds another layer of uncertainty. The National Library of Medicine’s LiverTox record on ibogaine summarizes safety concerns described in the medical literature, including serious adverse outcomes. This is why a person’s history cannot be reduced to a body-size calculation.
What raises risk?
Screening findings, medication interactions, and cardiac questions can change or halt a plan.
What support exists?
Monitoring, observation, and response capacity are part of the decision—not extras around it.
Formulations & terms / 04
Names for regimens do not create a personal protocol.
Literature and informal discussion may use terms such as flood, test, micro, or maintenance. These labels are not standardized safety categories. They can refer to different substances, formulations, goals, routes, intervals, study rules, or informal practices. They should never be treated as interchangeable pathways for personal dosing.
Likewise, hydrochloride is a defined salt form often discussed in research, while root bark or other botanical preparations can contain a changing mix of alkaloids. Product composition matters. A number associated with one preparation cannot be converted into an equivalent amount of another by a reader at home.
Questions about product identity also belong beside questions about measurement. The site’s explanation of how product quality is measured provides context for why composition, verification, and labeling are separate issues from a dose number. For alcohol-related concerns, a page on ibogaine and alcohol addiction may help distinguish broad interest in the topic from a safety decision about any individual.
- Flood is an informal term often used for larger, acute-exposure approaches described in some settings. It is not a recommendation.
- Test may describe an initial or divided amount in a particular protocol, but the rationale, monitoring, and exclusion rules cannot be carried into self-use.
- Micro and maintenance are used inconsistently across discussions. A label does not establish low risk, safety, or an appropriate schedule.
Clear boundary: no regimen label, published example, or anecdotal report can be converted into personal dosing advice. Never self-administer ibogaine or attempt to reproduce a study protocol.
Frequently asked / 05
The question behind the number is usually about risk.
“A reported dose is an observation from a context—not a permission slip outside it.”
-
Can published dose ranges be used as a personal calculation?
No. Published examples describe study or supervised-care contexts, not instructions for personal use. They do not account for individual medical history, medication interactions, cardiac findings, product identity, or monitoring capacity. Resources discussing what ibogaine does can describe mechanisms at a high level, but mechanism is not a self-dosing method.
-
Why do accounts from sport communities still not answer the question?
Individual stories cannot reveal everything that affected risk, screening, product composition, or follow-up. That limitation applies equally to material framed around ibogaine in rugby and discussions of ibogaine and soccer. Anecdote is not a clinical protocol.
-
Does cost tell you whether a setting is safe?
No. Price cannot verify medical screening, emergency readiness, product identity, or the quality of follow-up. Information about ibogaine retreat costs may describe financial considerations, but it cannot establish suitability or make unsupervised use safe.
Safety stays first
Screening changes the question before any dose is discussed.
For a focused look at eligibility limits, medication concerns, and the reasons a risk assessment may rule someone out, see the plain-language overview of risk and screening considerations. This page is educational only, not medical or legal advice, and not a protocol for personal use.